Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Young

Showing results (21-30 of 182) with videos related to

Pageof 19
Sort By:
Blood Advances|December 11, 2025
Emicizumab in infants: not just cost-effective but mandatoryGuy Young
Blood Advances|October 25, 2018
Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after toleranceGuy Young
Hemasphere|June 9, 2023
Nonfactor Therapies for HemophiliaGuy Young
Pediatric Blood & Cancer|October 6, 2005
Diagnosis and treatment of thrombosis in children: general principlesGuy Young
British Journal of Haematology|May 10, 2019
How I treat children with haemophilia and inhibitorsGuy Young
Journal of Thrombosis and Haemostasis : JTH|April 19, 2021
Management of children with hemophilia A: How emicizumab has changed the landscapeGuy Young
Pediatric Clinics of North America|November 28, 2017
Anticoagulation Therapies in ChildrenGuy Young
Pediatric Blood & Cancer|November 9, 2017
Deep vein thrombosis in pediatric patientsJulie Jaffray, Guy Young
Expert Opinion on Emerging Drugs|October 4, 2021
Emerging drugs for hemophilia A: insights into phase II and III clinical trialsHande Kizilocak, Guy Young
Pediatric Clinics of North America|November 19, 2013
Developmental hemostasis: clinical implications from the fetus to the adolescentJulie Jaffray, Guy Young
Pageof 19

Showing results (21-30 of 182) with videos related to

Sort By:
Pageof 19
Blood Advances|December 11, 2025
Emicizumab in infants: not just cost-effective but mandatoryGuy Young
Blood Advances|October 25, 2018
Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after toleranceGuy Young
Hemasphere|June 9, 2023
Nonfactor Therapies for HemophiliaGuy Young
Pediatric Blood & Cancer|October 6, 2005
Diagnosis and treatment of thrombosis in children: general principlesGuy Young
British Journal of Haematology|May 10, 2019
How I treat children with haemophilia and inhibitorsGuy Young
Journal of Thrombosis and Haemostasis : JTH|April 19, 2021
Management of children with hemophilia A: How emicizumab has changed the landscapeGuy Young
Pediatric Clinics of North America|November 28, 2017
Anticoagulation Therapies in ChildrenGuy Young
Pediatric Blood & Cancer|November 9, 2017
Deep vein thrombosis in pediatric patientsJulie Jaffray, Guy Young
Expert Opinion on Emerging Drugs|October 4, 2021
Emerging drugs for hemophilia A: insights into phase II and III clinical trialsHande Kizilocak, Guy Young
Pediatric Clinics of North America|November 19, 2013
Developmental hemostasis: clinical implications from the fetus to the adolescentJulie Jaffray, Guy Young
Pageof 19